|
CA2819510A1
|
|
Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta(g)quinazoline trisodium salt
|
|
SG187011A1
|
|
Synthesis of cyclopentaquinazolines
|
|
AU2005209653A1
|
|
Adenoviral vectors for treating disease
|
|
CN1934253A
|
|
Subgroup B adenoviral vectors for treating disease
|
|
CN1816619A
|
|
Method for purifying virus
|
|
US2004180418A1
|
|
Candida kefyr cytosine deaminase
|
|
US7078030B2
|
|
Oncolytic adenovirus
|
|
AU2002365899A1
|
|
RAF-MEK-ERK pathway inhibitors to treat cancer
|
|
US2004101512A1
|
|
Adenoviral vectors for treating disease
|
|
US7396679B2
|
|
Oncolytic adenovirus
|
|
CA2449013A1
|
|
Viral mutants that selectively replicate in targeted human cancer cells
|
|
AU1540202A
|
|
Guanine exchange factor of RHO GTPASE and nucleic acid encoding it
|
|
US6890747B2
|
|
Phosphoinositide 3-kinases
|
|
US2003087847A1
|
|
Method and reagent for the inhibition of checkpoint kinase-1 (Chk1) enzyme
|
|
EP1242116A2
|
|
Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
|
|
CN1450910A
|
|
Mutant simplex virus for treating hyperproliferative cell growth
|
|
US7001596B1
|
|
Oncolytic adenovirus
|
|
US6428960B1
|
|
Selection method for producing recombinant baculovirus
|
|
AU6621000A
|
|
Compositions and methods for regulating the cell cycle and other cellular processes involving the tgfbeta family
|
|
AU6057800A
|
|
Adenoviral vectors for treating disease
|
